Maxim Group Upgrades Vertex Pharmaceuticals to Buy, Announces $575 Price Target

Benzinga Newsdesk www.benzinga.com Positive 82.0%

Neg 0% Neu 0% Pos 82%

Maxim Group analyst Naz Rahman upgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Hold to Buy and announces $575 price target.